


geko[®] T3 device

VTE Prophylaxis

Providing venous thromboembolism (VTE) prophylaxis to all at risk hospital patients

The geko[®] T3 device is a small, wearable, single-use muscle pump activator (MPA) designed to increase blood flow in the deep veins of the leg¹, helping reduce the risk of venous thromboembolism (VTE)².

Powered by OnPulse[®] technology, the device gently stimulates the common peroneal nerve, activating the calf and foot muscle pumps to increase venous, arterial and microcirculatory blood flow^{2,3}.




Worn at the knee

Lightweight, discreet and comfortable



Stimulates the common peroneal nerve

Using OnPulse[®] neuromuscular electrostimulation



Activates the calf and foot muscle pump

Rhythmic muscle contractions increase blood flow^{3,4}



Increases blood flow in the deep veins of the calf

Equal to 60% of walking without the patient having to move⁴



Proven VTE Prophylaxis¹

Supported by NICE MTG19 Guidance



The geko[®] device is clinically proven to increase blood circulation across a range of in-hospital therapy areas, including the prevention of VTE.

Lightly
Medical



90.8%

The geko® T3 had a patient tolerance rate of 90.8%, significantly more favourable than the 78.2% tolerance rate for IPC³



103%

Increase in venous peak velocity with geko® vs 51% with IPC⁴

The geko® device prevents stasis in the deep veins of the calf where early thrombi form⁵

The geko® device increases blood flow in the deep veins in the lower limb⁵

The geko® device is 30% better than IPC at augmenting venous flow ($p < 0.001$)³



Zero DVT or PE events

in ~1,000 stroke patients using geko® T3 as primary prophylaxis, including patients where anticoagulation was contraindicated⁶



NICE Guidance support

NICE Guidance (MTG19) supports the use of the geko® device for people who have a high risk of VTE⁵

Self-adhesive and wearable, the geko® T3 is:

- Simple and easy to use
- Small and light (weighing just 10g) with no leads or wires, enables the patient to be as mobile as possible
- No tripping hazard

The geko® T3 is indicated to:

- increase blood circulation
- for the prevention of venous thrombosis
- for the prevention and treatment of oedema

Regulatory status

- FDA Cleared
- CE/MDR Marked
- TGA Registered
- Supported by NICE Guidance (MTG19)



Available in Australia and New Zealand through Lightly Medical



References

1. NICE Medical Technologies Guidance [MTG19] 2014
2. Tucker A et al. Int J Angiol. 2010;19(1):e31-7
3. Jawad H, Bain D, Dawson H, et al. J Vasc Surg. 2014.
4. Williams KJ, et al. Phlebology. 2014.
5. Griffin M, Nicolaides A, et al. J Int Angiol. 2016.
6. Natarajan S. Clinical outcomes in stroke patients managed with geko T3 as primary VTE prophylaxis where anticoagulation was contraindicated. Royal Stoke University Hospital. Data on file.

